drugset / Trial / NCT04887194

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

NCT04887194

Phase 1 Completed 40 enrolled Mirati Therapeutics Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

Study 516-010 is an open-label Phase 1, drug-drug interaction and QTc study evaluating the effect of sitravatinib on probe substrates for CYP450 enzymes and BCRP and P-gp transporters.

Timeline

Start
2021-04-08
Primary completion
2022-12-22
Completion
2022-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown
Subject Digoxin Other / unclassified
Subject Midazolam Small molecule
Subject Nivolumab Monoclonal antibody
Subject Rosuvastatin Small molecule
Subject Sitravatinib Small molecule
Subject Warfarin Small molecule

Indications

No indication recorded.